Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.805 USD | +0.28% | +0.11% | -4.63% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 15 | I-Mab Announces Chief Medical Officer Changes | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.63% | 145M | |
+25.89% | 672B | |
+25.86% | 570B | |
-6.14% | 360B | |
+15.57% | 321B | |
+8.46% | 300B | |
+7.08% | 217B | |
-9.20% | 204B | |
+5.11% | 199B | |
-9.07% | 149B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-Mab Doses First Phase 2 Clinical Trial of Efineptakin Alfa, Keyrtruda Combination in Advanced Solid Tumors